
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. is positioned for favorable growth driven by its innovative treatments, particularly Giapreza and Xacduro, which are addressing unmet needs in critical care and infectious disease markets. The company has demonstrated robust revenue momentum, with Xacduro sales projected to escalate from $2.0 million in 2023 to an annualized run rate of $95.3 million by 2025, alongside Giapreza showing consistent sales growth from $14.2 million in 2022 to an anticipated $55.0 million in 2024. Additionally, the company's strong patent protection and lower toxicity profile of its products position Innoviva for sustained commercial success and market competitiveness.
Bears say
Innoviva Inc's portfolio faces significant risks associated with its key healthcare assets, particularly in the context of growing antibiotic resistance impacting its product effectiveness in critical care and infectious disease markets. The company is dependent on the successful commercialization of its products, like ZEVTERA and zoliflodacin, which are challenged by factors such as competition from generics and declining sales for respiratory-focused products, thereby jeopardizing revenue generation. Furthermore, systemic risks, including macroeconomic volatility and potential long-term dilution, exacerbate the uncertainty surrounding Innoviva's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares